AR022820A1 - Compuestos derivados de piridopiranoacepinas, en forma de isomeros geometricos u opticos puros o de mezcla de tales isomeros, procedimiento para su preparacion, medicamento y composicion farmaceutica. - Google Patents
Compuestos derivados de piridopiranoacepinas, en forma de isomeros geometricos u opticos puros o de mezcla de tales isomeros, procedimiento para su preparacion, medicamento y composicion farmaceutica.Info
- Publication number
- AR022820A1 AR022820A1 ARP000100942A ARP000100942A AR022820A1 AR 022820 A1 AR022820 A1 AR 022820A1 AR P000100942 A ARP000100942 A AR P000100942A AR P000100942 A ARP000100942 A AR P000100942A AR 022820 A1 AR022820 A1 AR 022820A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- piridopiranoacepinas
- isomeros
- medicinal
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 230000003287 optical effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- -1 cyano, hydroxy, nitro, acetyl Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 210000005095 gastrointestinal system Anatomy 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compuestos de la formula general (1) en la cual: R1 representa un átomo de hidrogeno, un grupo alquilo, fenilalquilo, fenilhidroxialquilo, furanilalquilo ofuranilhidroxialquilo; R2 representa ya sea un átomo de hidrogeno o de halogeno o un grupotrif luorometilo, ciano, hidroxi, nitro, acetilo, alquilo, alcoxi,amino de formula general NR4R5 en la cual R4 y R5 representan cada uno un átomo de hidrogeno o un grupo alquilo o forman, con el átomo de nitrogeno que loscontiene, un ciclo en C4-7,ya sea un grupo fenilo o naftilo eventualmente sustituido por un átomo de halogeno o un grupo trifluorometilo, trifluorometoxi,ciano, hidroxi, nitro, acetilo, alquilo, alcoxi o metilendioxi; y R3 representa un átomo de hidrogeno o de halogeno o ungrupo al quilo. Uso: tratamiento oprevencion de desordenes relacionados con una disfuncion de los receptores nicotínicos, sobre todo al nivel del SNC o del sistema gastrointestinal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9902784A FR2790474B1 (fr) | 1999-03-05 | 1999-03-05 | Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR022820A1 true AR022820A1 (es) | 2002-09-04 |
Family
ID=9542888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100942A AR022820A1 (es) | 1999-03-05 | 2000-03-03 | Compuestos derivados de piridopiranoacepinas, en forma de isomeros geometricos u opticos puros o de mezcla de tales isomeros, procedimiento para su preparacion, medicamento y composicion farmaceutica. |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US6538003B1 (es) |
| EP (1) | EP1161434B1 (es) |
| JP (1) | JP4806123B2 (es) |
| KR (2) | KR100768355B1 (es) |
| CN (1) | CN1137894C (es) |
| AR (1) | AR022820A1 (es) |
| AT (1) | ATE231869T1 (es) |
| AU (1) | AU764625B2 (es) |
| BG (1) | BG65211B1 (es) |
| BR (1) | BR0008763A (es) |
| CA (1) | CA2372063C (es) |
| CO (1) | CO5160250A1 (es) |
| CZ (1) | CZ302259B6 (es) |
| DE (1) | DE60001307T2 (es) |
| DK (1) | DK1161434T3 (es) |
| EE (1) | EE04497B1 (es) |
| ES (1) | ES2191611T3 (es) |
| FR (1) | FR2790474B1 (es) |
| HK (1) | HK1040398B (es) |
| HR (1) | HRP20010655B1 (es) |
| HU (1) | HU228671B1 (es) |
| ID (1) | ID30116A (es) |
| IL (2) | IL145150A0 (es) |
| MX (1) | MXPA01008972A (es) |
| NO (1) | NO327119B1 (es) |
| NZ (1) | NZ513561A (es) |
| PE (1) | PE20001543A1 (es) |
| PL (1) | PL201683B1 (es) |
| RS (1) | RS49997B (es) |
| RU (1) | RU2238273C2 (es) |
| SK (1) | SK284339B6 (es) |
| TR (1) | TR200102403T2 (es) |
| TW (1) | TWI222975B (es) |
| UA (1) | UA61164C2 (es) |
| UY (1) | UY26048A1 (es) |
| WO (1) | WO2000053608A1 (es) |
| ZA (1) | ZA200106811B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| CA2487849A1 (en) | 2002-07-18 | 2004-01-29 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
| ATE378048T1 (de) * | 2002-12-06 | 2007-11-15 | The Feinstein Inst Medical Res | Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten |
| US7238715B2 (en) * | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| US8580842B2 (en) * | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
| US20080255203A1 (en) * | 2007-04-12 | 2008-10-16 | Abbott Laboratories | Heterocyclic compounds and their methods of use |
| US20090076059A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched dianicline |
| CN101952276B (zh) * | 2007-12-07 | 2014-10-22 | Abbvie德国有限责任两合公司 | 5-卤素取代的羟吲哚衍生物和其用于治疗加压素依赖性疾病的用途 |
| EP2231644B1 (de) | 2007-12-07 | 2014-01-15 | AbbVie Deutschland GmbH & Co KG | 5,6-Disubstitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen |
| US8703774B2 (en) | 2007-12-07 | 2014-04-22 | AbbVie Deutschland GmbH & Co. KG | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases |
| EP2231643B1 (de) | 2007-12-07 | 2012-10-31 | Abbott GmbH & Co. KG | Amidomethyl-substitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen |
| US20090221648A1 (en) * | 2007-12-21 | 2009-09-03 | Abbott Laboratories | Compositions for treatment of cognitive disorders |
| US8383657B2 (en) * | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
| EP2271344A4 (en) | 2008-03-31 | 2011-04-27 | Univ South Florida | METHOD FOR TREATING ILLNESS-RELATED ATAXIA AND NON-ATTACHIC IMBALANCE |
| KR20140146216A (ko) | 2008-11-19 | 2014-12-24 | 포럼 파마슈티칼즈 인크. | (ｒ)-７-클로로-ｎ-(퀴누클리딘-３-일)벤조［ｂ］티오펜-２-카르복사미드 및 그 약학적으로 허용가능한 염을 이용한 인지 장애의 치료 |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| MX2011011972A (es) * | 2009-05-11 | 2011-12-08 | Envivo Pharmaceuticals Inc | Tratamiento de trastornos cognitivos con determinados receptores de acido nicotinico alfa-7 en combinacion con inhibidores de acetilcolinesterasa. |
| US9040568B2 (en) * | 2009-05-29 | 2015-05-26 | Abbvie Inc. | Pharmaceutical compositions for the treatment of pain |
| PL3029039T3 (pl) | 2010-05-17 | 2018-04-30 | Forum Pharmaceuticals Inc. | Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu |
| HK1208356A1 (en) | 2012-05-08 | 2016-03-04 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3008226B2 (ja) * | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| GB9301660D0 (en) * | 1993-01-28 | 1993-03-17 | Smithkline Beecham Plc | Pharmaceuticals |
| WO1997011072A1 (en) * | 1995-09-22 | 1997-03-27 | Novo Nordisk A/S | Novel substituted azacyclic or azabicyclic compounds |
| FR2761072B1 (fr) * | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique |
| CN1110499C (zh) * | 1997-05-30 | 2003-06-04 | 神经研究公司 | 螺一奎宁环衍生物,它们的制备和用途 |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
-
1999
- 1999-03-05 FR FR9902784A patent/FR2790474B1/fr not_active Expired - Fee Related
-
2000
- 2000-01-03 UA UA2001085808A patent/UA61164C2/uk unknown
- 2000-03-01 KR KR1020017011245A patent/KR100768355B1/ko not_active Expired - Fee Related
- 2000-03-01 DK DK00907746T patent/DK1161434T3/da active
- 2000-03-01 RU RU2001123126/04A patent/RU2238273C2/ru not_active IP Right Cessation
- 2000-03-01 JP JP2000604044A patent/JP4806123B2/ja not_active Expired - Fee Related
- 2000-03-01 ID IDW00200101796A patent/ID30116A/id unknown
- 2000-03-01 HK HK02101759.7A patent/HK1040398B/zh not_active IP Right Cessation
- 2000-03-01 ES ES00907746T patent/ES2191611T3/es not_active Expired - Lifetime
- 2000-03-01 PL PL352330A patent/PL201683B1/pl unknown
- 2000-03-01 MX MXPA01008972A patent/MXPA01008972A/es unknown
- 2000-03-01 EP EP00907746A patent/EP1161434B1/fr not_active Expired - Lifetime
- 2000-03-01 US US09/913,679 patent/US6538003B1/en not_active Expired - Lifetime
- 2000-03-01 CA CA2372063A patent/CA2372063C/en not_active Expired - Fee Related
- 2000-03-01 DE DE60001307T patent/DE60001307T2/de not_active Expired - Lifetime
- 2000-03-01 RS YUP-596/01A patent/RS49997B/sr unknown
- 2000-03-01 BR BR0008763-7A patent/BR0008763A/pt not_active Application Discontinuation
- 2000-03-01 AT AT00907746T patent/ATE231869T1/de active
- 2000-03-01 CN CNB008046662A patent/CN1137894C/zh not_active Expired - Fee Related
- 2000-03-01 NZ NZ513561A patent/NZ513561A/xx not_active IP Right Cessation
- 2000-03-01 HR HR960321A patent/HRP20010655B1/xx not_active IP Right Cessation
- 2000-03-01 WO PCT/FR2000/000502 patent/WO2000053608A1/fr not_active Ceased
- 2000-03-01 CZ CZ20013102A patent/CZ302259B6/cs not_active IP Right Cessation
- 2000-03-01 AU AU29226/00A patent/AU764625B2/en not_active Ceased
- 2000-03-01 SK SK1242-2001A patent/SK284339B6/sk not_active IP Right Cessation
- 2000-03-01 HU HU0201753A patent/HU228671B1/hu not_active IP Right Cessation
- 2000-03-01 TR TR2001/02403T patent/TR200102403T2/xx unknown
- 2000-03-01 CO CO00014724A patent/CO5160250A1/es unknown
- 2000-03-01 IL IL14515000A patent/IL145150A0/xx active IP Right Grant
- 2000-03-01 EE EEP200100470A patent/EE04497B1/xx not_active IP Right Cessation
- 2000-03-01 KR KR1020077013746A patent/KR20070086359A/ko not_active Withdrawn
- 2000-03-03 UY UY26048A patent/UY26048A1/es not_active IP Right Cessation
- 2000-03-03 PE PE2000000187A patent/PE20001543A1/es not_active Application Discontinuation
- 2000-03-03 AR ARP000100942A patent/AR022820A1/es active IP Right Grant
- 2000-03-08 TW TW089103753A patent/TWI222975B/zh not_active IP Right Cessation
-
2001
- 2001-08-16 BG BG105828A patent/BG65211B1/bg unknown
- 2001-08-17 ZA ZA200106811A patent/ZA200106811B/en unknown
- 2001-08-28 IL IL145150A patent/IL145150A/en not_active IP Right Cessation
- 2001-09-03 NO NO20014270A patent/NO327119B1/no not_active IP Right Cessation
-
2003
- 2003-02-06 US US10/359,881 patent/US6908927B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR022820A1 (es) | Compuestos derivados de piridopiranoacepinas, en forma de isomeros geometricos u opticos puros o de mezcla de tales isomeros, procedimiento para su preparacion, medicamento y composicion farmaceutica. | |
| AR056544A1 (es) | Derivados fenilaminopropanol y metodos de uso de los mismos | |
| AR091400A2 (es) | Composicion farmaceutica que comprende derivados de sulfamida, proceso para prepararla y uso de dichos compuestos para preparar medicamentos | |
| PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
| AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
| AR057984A1 (es) | DERIVADOS DE IMIDAZOL INHIBIDORES DE LA PROTEINA beta AMILOIDE | |
| AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
| AR072839A1 (es) | Derivados adamantil diamida y usos de los mismos | |
| AR058769A1 (es) | Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. | |
| ES2185338T3 (es) | Derivados de fumagilol y procedimientos para su fabricacion. | |
| AR033735A1 (es) | Compuestos de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR038863A1 (es) | Uso de un inhibidor de garft y/o de aicarft y de un agente antitoxico para preparar un medicamento para destruir selectivamente celulas mtap-deficientes de un mamifero | |
| AR035532A1 (es) | Diaminotiazoles, composiciones farmaceuticas que los comprenden, intermediarios para la preparacion de dichos compuestos, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos | |
| AR044829A1 (es) | Derivados de bis-4-cloro fenil pirazinas | |
| AR057981A1 (es) | Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion | |
| AR046793A1 (es) | Derivados de pirazol, antagonistas del receptor de la orexina | |
| CO4950553A1 (es) | Compuestos de 7-tetrahidroisoquinolinas y procedimiento para su preparacion | |
| AR069800A1 (es) | Derivados 5- aminociclilmetil - oxazolidin-2- ona | |
| AR027296A1 (es) | Derivados de 4-heteroaril-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion terapeutica | |
| AR044883A1 (es) | Derivados del 8-aza-biciclo [3.2.1] octano y su uso como inhibidores de la recaptacion de neurotransmisores monoaminicos | |
| AR035230A1 (es) | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos | |
| CO5160242A1 (es) | UTILIZACION DE DERIVADOS DE PIRIDAZINO [4,5-b] INDOL-1- ACETAMIDA, PARA LA PREPARACION DE MEDICAMENTOS DESTINADOS A LAS ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL | |
| AR042155A1 (es) | Aminoalcoxiindoles, composicion farmaceutica que los comprenden y usos | |
| AR054083A1 (es) | Compuestos imidazol y su utilizacion paar preparar medicamentos | |
| AR048317A1 (es) | Derivados de benzoazepina como antagonistas del receptor muscarinico de acetilcolina y composiciones farmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration |